Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target
Stifel kept a Buy rating on ORIC Pharmaceuticals with a $18.00 price target, implying 36.7% upside from the Oct 23 close. The firm cited encouraging Phase 1b data for enozertinib and reduced risks for the MEVPRO-1 trial as reasons for the rating.
How this was made

The 30-second read
Why it matters
The data could trigger a short‑term rally and attract new long positions, especially given the $18 target versus current price.
Market read
The announcement offers a concrete catalyst for ORIC and may influence peer biotech valuations.
What to watch
Potential competition from other EGFR therapies and regulatory timelines could temper upside.
Background
Stifel's note highlights new clinical data and a de‑risking of ORIC's pipeline, providing fresh analyst coverage.
Ticker impact
Stifel upgraded ORIC with a Buy rating and $18 price target after releasing Phase 1b data showing 84% response rate in EGFR‑mutant NSCLC.
likely upward pressure as investors price in the strong response rate and de‑risking of the upcoming Phase 3 trial.
Phase 1b data is material for biotech valuations; the upgrade and target raise provide a clear near‑term catalyst.
Market effects
Strengthens the broader EGFR‑mutant NSCLC therapeutic space and may lift peer biotech sentiment.
U.S. biotech sector could see modest gains on the back of the data.
Limited to biotech investors; no broad market effect.
Counterpoint
Some investors may remain cautious until Phase 3 data, viewing early‑stage results as preliminary.
Key entities
- companyORIC Pharmaceuticals
Biotech firm developing EGFR‑mutant NSCLC therapies.
- analystStifel
Equity research firm issuing the Buy rating.
